Strategic partner for lifescience innovators

We help BioPharma and MedTech organisations optimise Market Access and Pre‑Launch/Launch Business Planning, so patients have timely access to the medicines and devices they need to improve health outcomes.

Our Services Get in touch

BioPharma & MedTech Consultancy

What we do

Strategic clarity. Effective execution.

Deep expertise across Market Access, Business Strategy, and Leadership — tailored to the complexity of lifesciences.

Market Access

Strategic clarity enabling effective execution

We support companies to define access strategy, address access challenges, and identify solutions.

  • Tailored Market Access Strategy
  • Pricing & Reimbursement including Mock Negotiations
  • HEOR & RWE planning
  • Advisory Boards
  • Compelling Value Proposition
Kaplan–Meier Survival Analysis Evidence 1.0 0.75 0.50 0.25 0 Survival probability 0 6 12 18 24 30 Time (months) HR 0.62 (95% CI 0.48–0.79) p < 0.001 (log-rank) mOS: 24.3 vs 14.8 months Treatment arm (n=183) Control arm (n=179) At risk: 183 156 124 88 42 11

Business Strategy

Your keystone for success

From concept validation to commercialisation — clear strategy as a foundation, insights to inform decisions, and a plan to execute effectively.

  • Business strategy for BioPharma & MedTech
  • Founder & Start-Up support
  • Feasibility & concept evaluation
  • Integrated Market Access & Commercial Planning
  • Go-to-Market model

Leadership & Executive Coaching

Empowering you to be your best self

Extensive experience in the lifesciences industry as a mentor and coach — empowering individuals and teams to close the gap, between where you are and achieving your full potential.

  • Confidential sounding board for senior leaders
  • Local to Regional/Global transition support
  • Career coaching
  • Mentoring for Lifesciences & STEM graduates
Muireann McAlister

Muireann McAlister

Principal Consultant

About Us

Established 2026

Muireann McAlister brings over 30 years of BioPharma industry experience across Market Access, Strategic Commercial Leadership, and International Clinical Trials — with senior leadership roles both locally and above-country.

She has launched multiple innovative medicines and led over 30 successful HTA submissions and reimbursement negotiations across diverse therapeutic areas. In her global role she led collaboration across international developed markets, driving implementation of access strategy, pricing strategy, and health economic outcomes research to deliver growth.

Over 15 years of extensive involvement with IPHA and EFPIA working groups. Passionate about patient access and the enduring potential of science to improve health outcomes for patients, healthcare systems, and society.

Get in touch

Let's talk about your project

Tell us about your organisation and how we can support you.